The Novo, Pfizer and Nan Fung-backed oncology therapy developer priced an upsized offering above its range and is now valued above $1bn.
Author: Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
NexWafe shines in $12m series B
Saudi Aramco Energy Ventures returned to contribute to a round that will support development of a pilot version of NexWafe’s solar wafer production technology.
Inivata inflates series C round to $60m
Johnson & Johnson-backed cancer biospy developer Inivata has added $35m to a series C round anchored by $25m from NeoGenomics in May.
Eli Lilly helps Auron organise seed funding
The cancer drug developer’s $12.8m seed round included Eli Lilly, and Lilly New Ventures’ Brad Robling is a board observer.
Span measures out $20m
Munich Re Ventures’ HSB Fund led a consortium for the fuse box technology developer’s series B round that included Amazon’s Alexa Fund.
4Paradigm charts $700m series D
China Three Gorges, Cisco and Lenovo-backed 4Paradigm has closed a $700m series D round after more than a dozen backers threw their weight behind the enterprise AI developer.
TripActions books $155m series E
Lufthansa’s portfolio company TripActions has attracted $155m in series E financing co-led by Andreessen Horowitz, Addition and Elad Gil at a valuation of $5bn.
Decipher Biosciences to penetrate public markets
UnitedHealth Group and Merck & Co are both in line for exits as Decipher Biosciences files for a $100m initial public offering.
APX reaches $67m fund summit
The early-stage investor backed by Porsche and Axel Springer now has $67m under management and will aim to add some 130 companies to its portfolio by 2022.
GUV’s top 10 of 2020
Sister publication Global University Venturing’s top 10 most-read features of 2020.
BHP helps pour $50m into Boston Metal
BHP Ventures is co-leading the steel manufacturing technology developer’s series B round, which has a $60m target for its close.
Investors roll Dice to $80m series C
Sanofi Ventures contributed to a series C round for Dice Molecules, which is advancing a potential psoriasis treatment.
The fork in the road
Global University Venturing: tech transfer leaders and investors should set a precedent
Kira comes out of stealth with $46m
Sinopharm Capital and the WuXi AppTec-backed 6 Dimensions Capital are among the investors in the inflammatory and autoimmune disease drug developer.